Abstract

Antiplatelet therapy plays a pivotal role in modern management of coronary artery disease and use of clopidogrel has facilitated the emergence of intravascular stenting as common cardiological practice. However, clopidogrel responsiveness is heterogeneous within the population, with a sizable proportion seemingly non-responsive to its antiplatelet effects and at higher risk of cardiovascular events as a result [1, 2].